Just the Facts on Acorda Therapeutics, Inc. (ACOR)

Acorda Therapeutics, Inc. (ACOR) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $30.40, up from yesterday’s close by 8.96%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Acorda Therapeutics, Inc. (ACOR) currently trades with a market capitalization of $1.41 Billion. That value represents a market adjusting for revenues that have been falling by -11.07 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $138.16 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.65 on a per share basis this quarter. Perhaps, that suggests something about why 2.35% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Acorda Therapeutics, Inc. recorded a 52-week high of $29.60. It is now trading -0.8% off that level. The stock is trading $24.10 its 50-day moving average by -6.3%. The stock carved out a 52-week low down at $15.17.

In recent action, Acorda Therapeutics, Inc. (ACOR) has made a move of +28.81% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.04, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 12.82% with $46.20 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ACOR.

Previous articleThe Case for and Against eBay Inc. (EBAY)
Next articleTaking a Look at the Data Behind Gilead Sciences, Inc. (GILD)